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Myeloproliferative neoplasms (MPNs), including essential thrombocytosis, polycythemia vera, and primary myelo-
fibrosis, present as clonal expansions of ≥1 myeloid lineages.1 In 
2005, several groups identified somatic JAK2V617F (JAK2VF) 
mutations in ≈95% of polycythemia vera patients and in ≈50% 
to 60% of essential thrombocytosis and primary myelofibro-
sis patients.2–6 The mutation activates JAK2 (Janus kinase 2) 
and downstream signaling pathways2,7 leading to proliferation 
of hematopoietic stem and progenitor cells. MPN patients are 
at significantly increased risk of atherothrombotic events, in-
cluding cardiac ischemic events and thrombotic stroke.8 More 
recently, DNA sequencing of subjects in the general popula-
tion has shown that >10% of people aged ≥70 have clones of 
blood cells bearing mutations that have been associated with 
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Rationale: The mechanisms driving atherothrombotic risk in individuals with JAK2V617F (Jak2VF) positive clonal 
hematopoiesis or myeloproliferative neoplasms are poorly understood.
Objective: The goal of this study was to assess atherosclerosis and underlying mechanisms in hypercholesterolemic 
mice with hematopoietic Jak2VF expression.
Methods and Results: Irradiated low-density lipoprotein receptor knockout (Ldlr−/−) mice were transplanted with bone 
marrow from wild-type or Jak2VF mice and fed a high-fat high-cholesterol Western diet. Hematopoietic functions and 
atherosclerosis were characterized. After 7 weeks of Western diet, Jak2VF mice showed increased atherosclerosis. Early 
atherosclerotic lesions showed increased neutrophil adhesion and content, correlating with lesion size. After 12 weeks of 
Western diet, Jak2VF lesions showed increased complexity, with larger necrotic cores, defective efferocytosis, prominent iron 
deposition, and costaining of erythrocytes and macrophages, suggesting erythrophagocytosis. Jak2VF erythrocytes were 
more susceptible to phagocytosis by wild-type macrophages and showed decreased surface expression of CD47, a “don’t-
eat-me” signal. Human JAK2VF erythrocytes were also more susceptible to erythrophagocytosis. Jak2VF macrophages 
displayed increased expression and production of proinflammatory cytokines and chemokines, prominent inflammasome 
activation, increased p38 MAPK (mitogen-activated protein kinase) signaling, and reduced levels of MerTK (c-Mer 
tyrosine kinase), a key molecule mediating efferocytosis. Increased erythrophagocytosis also suppressed efferocytosis.
Conclusions: Hematopoietic Jak2VF expression promotes early lesion formation and increased complexity in 
advanced atherosclerosis. In addition to increasing hematopoiesis and neutrophil infiltration in early lesions, Jak2VF 
caused cellular defects in erythrocytes and macrophages, leading to increased erythrophagocytosis but defective 
efferocytosis. These changes promote accumulation of iron in plaques and increased necrotic core formation 
which, together with exacerbated proinflammatory responses, likely contribute to plaque instability.  (Circ Res. 
2018;123:e35-e47. DOI: 10.1161/CIRCRESAHA.118.313283.)
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hematologic malignancies, primarily loss of function variants 
in epigenetic modifiers TET2, ASXL1, DNTM3A, as well as 
JAK2VF. Although clonal hematopoiesis (CH) was associated 
with an increased risk of hematologic malignancies, unexpect-
edly there was also a 2 to 3 fold increase in the risk of ather-
osclerotic cardiovascular disease (CVD), identifying CH as a 
major risk factor for CVD in the elderly. Moreover, the prev-
alence of CH increases from age 40 years onward, and CH 
mutations increase the risk of early-onset myocardial infarc-
tion (<50 years old) by 4 fold. Although less common than 
the epigenetic modifier variants, the increase in risk appears to 
be strongest for the JAK2VF variant (12-fold increase in CVD). 
Although the association of CH with atherosclerosis in human 
populations could be confounded by aging, a causal relation-
ship between TET2 deficiency and atherosclerosis was shown 
in mouse models with pan-hematopoietic or myeloid TET2 
deficiency, and increased macrophage inflammation was im-
plicated as an underlying mechanism.9,10 Whether the same or 
different atherogenic mechanisms are involved in the effects 
of other CH mutations is not known. In this study, we have 
assessed atherosclerosis in mice with hematopoietic Jak2VF ex-
pression and explored the underlying mechanisms.
Methods
The authors declare that all supporting data, analytical methods, and 
materials developed from this group within the article and its Online 
Data Supplement files are available.
A detailed description of methods and materials is provided in the 
Online Data Supplement.
Results
Increased Atherosclerosis in Jak2VF Mice
To assess the impact of hematopoietic Jak2VF expression on 
atherosclerosis, sublethally irradiated wild-type (WT) or 
Ldlr−/− mice were transplanted with WT or Jak2VF expressing 
bone marrow (BM) cells.11 To assess a possible interaction of 
the mutation with hypercholesterolemia, WT recipients were 
fed a chow diet, and Ldlr−/− recipients were fed Western diet 
(WD). Although WT recipients fed the chow diet remained 
normocholesterolemic, WD feeding caused progressive hy-
percholesterolemia in Ldlr−/− recipients (Online Figure IA). 
However, the increase in plasma cholesterol caused by the 
WD was less pronounced in the Ldlr−/− mice receiving Jak2VF 
BM (≈30% lower after 7 weeks; P<0.01), reflecting reduced 
VLDL (very low-density lipoprotein)+LDL cholesterol lev-
els as shown elsewhere,12 which may reflect increased uptake 
of LDL by expanded myeloid cells13 or inflammatory cyto-
kine effects on hepatic production.14 Plasma HDL (high-den-
sity lipoprotein) cholesterol in WD-fed mice (Online Figure 
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• Acquired activating mutations of JAK2 notably JAK2V617F (JAK2VF) 
drive development of clonal hematopoiesis and myeloproliferative 
neoplasms.
• JAK2VF positive clonal hematopoiesis and myeloproliferative neo-
plasms are associated with increased atherothrombotic risk, but the 
underlying mechanisms are poorly understood.
What New Information Does This Article Contribute?
• Hematopoietic Jak2VF expression in Ldlr−/− mice promotes neutrophil-
enriched early lesion formation.
• Advanced lesions show increased necrotic cores, defective efferocyto-
sis, and prominent erythrophagocytosis
• Jak2VF macrophages displayed increased expression of proinflamma-
tory cytokines and inflammasome activation, possibly driving neutro-
phil entry into lesions.
• Jak2VF erythrocytes undergo increased uptake by macrophages 
(erythrophagocytosis), leading to impaired uptake of apoptotic cells 
(efferocytosis), which together with increased cleavage of MerTK 
(c-Mer tyrosine kinase), promotes necrotic core formation and plaque 
instability.
Jak2VF, a gain of function mutation that is commonly found in 
elderly patients with myeloproliferative neoplasms or clonal he-
matopoiesis, is associated with increased risk of atherothrom-
botic diseases. In Ldlr−/− mice expressing Jak2VF in hematopoietic 
tissues, we showed accelerated early atherosclerosis and in-
creased complexity of advanced lesions, despite lower levels of 
LDL (low-density lipoprotein) cholesterol. Early lesions showed 
increased binding of neutrophils to endothelium and increased 
numbers of neutrophils in plaques. More advanced lesions 
showed increased necrotic cores, defective efferocytosis, and 
erythrophagocytosis. Erythrophagocytosis refected a Jak2VF in-
trinsic red cell defect. Defective efferocytosis was linked to mac-
rophage inflammation and MerTK cleavage and to competition 
between red cells and apoptotic cells for macrophage uptake. 
These studies provide direct evidence that Jak2VF increases ath-
erogenesis, involving different hematopoietic lineages and their 
interactions.
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IB) or plasma total cholesterol in chow diet–fed mice (Online 
Figure IC) showed no change. Plasma triglyceride levels 
were also decreased in WD-fed Jak2VF recipients (Online 
Figure ID). Relative to the WT recipients, Jak2VF recipients 
displayed expansion of hematopoietic stem and progenitor 
cells, erythrocyte, and megakaryocyte progenitors in BM 
(Online Figure IE) and marked erythrocytosis, thrombocy-
tosis, and neutrophilia (Online Figure IF–IJ), as reported,11 
on both chow and WD diets. There was marked erythrocyte 
microcytosis and anisocytosis (Online Figure IIA and IIB). 
Jak2VF also markedly increased platelet/monocyte and plate-
let/neutrophil aggregates (Online Figure IIC and IID), likely 
reflecting increased platelet and leukocyte counts and in-
creased platelet activation as evidenced by increased surface 
P-selectin presentation in the basal or PAR4 (protease-acti-
vated receptor) agonist (AYPGKF)-stimulated state (Online 
Figure IIE and IIF). The increases in hematopoietic stem 
and progenitor cell counts (Online Figure IE), neutrophilia 
(Online Figure IJ), platelet/monocyte and platelet/neutrophil 
aggregates (Online Figure IIC and IID), and platelet surface 
P-selectin (Online Figure IIE) in Jak2VF were significantly 
more pronounced on the WD (P<0.05) as assessed by 2-way 
ANOVA and Sidak post hoc test for multiple comparisons.
Despite the lower plasma cholesterol levels, atherosclerotic 
lesion size in the aortic root was increased by 1.6 fold in Jak2VF 
recipients fed WD for 7 weeks (Figure 1A), indicating a potent 
proatherogenic impact of Jak2VF. Consistent with the pronounced 
neutrophilia, there was a marked increase in neutrophils in early 
lesions of Jak2VF recipients (shown by Ly6G staining; Figure 1B 
and 1C; Online Figure IIIA), whereas macrophage content was 
unchanged (Online Figure IIIB). Lesional MPO (myeloperoxi-
dase), another neutrophil marker which largely overlapped with 
the Ly6G marker in lesional cells (Figure 1B), was also markedly 
increased in early lesions of Jak2VF recipients (Figure 1D) and 
correlated with lesion size (Figure 1E), consistent with a proath-
erogenic role of neutrophils in early atherogenesis.15 Intravital 
fluorescence microscopy showed a marked increase in neutro-
phil rolling and firm adhesion on early carotid artery lesions in 
Jak2VF recipients (Figure 2A–2C); monocyte rolling, but not 
adhesion, was significantly increased (Online Figure IIIC and 
Figure 1. Increased early atherosclerotic lesions and neutrophil infiltration in Jak2VF mice. A, Representative H&E (hematoxylin and eosin)-stained 
aortic root lesions and quantification of total lesion area of female Ldlr−/− recipients after 7 wk of Western diet (WD). Mann-Whitney U test. Scale bar, 500 
μm. B, Representative immunofluorescence images of MPO (myeloperoxidase; green) and Ly6G (Red) with 4′,6-diamidino-2-phenylindole (DAPI; Blue) of 
aortic root lesions from female mice fed WD for 7 wk. Mann-Whitney U test. Scale bar,100 μm. C, Quantification of Ly6G positive cells (Mann-Whitney U 
test) and (D) MPO-positive cells in the lesions. Unpaired t test. E, Correlation between MPO+ neutrophils and total lesion size after 7 wk of WD. *P<0.05, 
**P<0.01. Spearman correlation test. Lu indicates lumen; and WT, wild-type.
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IIID). Neutrophils from WD-fed Jak2VF recipients showed evi-
dence of activation with increased expression of FPR1 (formyl 
peptide receptor 1) and adhesion molecule CD11b (Figure 2D 
and 2E). Neutrophils displayed increased adhesion to recombi-
nant cell adhesion molecules (Figure 2F and 2G). Thus, in ad-
dition to neutrophilia, neutrophil activation likely contributed to 
increased adhesion and entry of neutrophils into early athero-
sclerotic plaques.
In mice fed the WD for 12 weeks, plasma total cholesterol and 
triglyceride levels were ≈50% lower in Jak2VF recipients (Online 
Figure IVA and IVB). Despite the markedly reduced cholesterol 
and triglyceride levels, lesion size showed a trend to be increased 
(1.3 fold; P=0.07) in the Jak2VF recipients (Figure 3A). Necrotic 
core area, a well-established index of plaque instability,16 was sig-
nificantly increased both in absolute terms (area of necrotic core 
per section, 1.7 fold increase) or relative to lesion size (% of total 
lesion area, 1.4 fold increase; Figure 3B–3D) in Jak2VF recipients 
compared with controls. Lesional macrophages (Figure 3E), but 
not neutrophils, (Online Figure IVC) were increased in advanced 
lesions of Jak2VF recipients. Unlike in early lesions, lesional neu-
trophil count showed no significant correlation with lesion area 
in advanced lesions (Online Figure IVD). Collagen content and 
fibrous cap thickness did not show differences between the geno-
types in advanced lesions (Online Figure IVE).
Figure 2. Increased rolling and adhesion of neutrophils in Jak2VF mice. Female Ldlr−/− recipients were fed Western diet for 5 wk. A, Representative image 
of epifluorescence intravital microscopy of the carotid artery showing interaction of Ly6G-stained neutrophils with the arterial vessel wall. Arrow indicates 
flow direction. Scale bar, 50 μm. B, Quantification of Ly6G-stained neutrophil adhesion in the carotid artery by intravital microscopy. Mann-Whitney U test. 
C, Neutrophil rolling flux was assessed by intravital microscopy. Expression of (D) FPR1 (formyl peptide receptor 1) and (E) CD11b MFI (mean fluorescence 
intensity) on neutrophils were measured by flow cytometry. Mann-Whitney U test. F and G, Flow chamber assays for neutrophil adhesion using equal number 
of neutrophils. F, Representative images and (G) quantification of adhesion. Mann-Whitney U test. Scale bar, 50 μm. *P<0.05, ***P<0.001. AA indicates 
auricular artery; ECA, external carotid artery; LA, lingual artery; and WT, wild-type.
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Jak2VF Increases Lesional Erythrophagocytosis in 
Advanced Atherosclerosis
Increased hematocrit, as well as abnormalities in red blood 
cell (RBC) morphology in Jak2VF mice (Online Figure IF; 
Online Figure IIA and IIB), suggested a possible role of eryth-
rocytes in atherosclerosis.17 To assess this, we stained lesions 
for iron and erythrocytes. Although WT recipients showed lit-
tle lesional iron deposition, iron staining was clearly identi-
fied in the majority of Jak2VF recipients in advanced lesions 
(Figure 4A; Online Figure IVF, P<0.05, χ2 test). Staining of 
Ter119, a specific erythrocyte marker, was also increased in ad-
vanced lesions of Jak2VF recipients (Figure 4A, Online Figure 
IVG, P<0.05, χ2 test). Interestingly, when the Ter119 positive 
sections were stained with antibodies against the macrophage 
marker Mac-3 (CD107b), the 2 markers were largely colocal-
ized (Figure 4A), suggesting erythrophagocytosis. Notably, 
macrophages containing erythrocyte markers were primarily 
found on the periphery of necrotic cores (Figure 4A), particu-
larly in 7 week early lesions (Online Figure VA).
To assess potential pathways for entry of RBCs into le-
sions, we assessed VWF (von Willebrand factor) staining. 
However, there was little staining in advanced lesions and no 
difference between Jak2VF and WT recipients (not shown). We 
did detect a marked increase in erythrocyte/neutrophil and e-
rythrocyte/monocyte complexes in the circulation in Jak2VF 
recipients (Online Figure VB), suggesting the possibility that 
erythrocyte/leukocyte complex formation facilitates RBC en-
try via the luminal surface of plaques.
Jak2VF Erythrocytes Are More Susceptible to 
Erythrophagocytosis
To gain insights into the mechanism of erythrophagocytosis in 
lesions, we incubated WT or Jak2VF erythrocytes with WT or 
Jak2VF macrophages and assessed erythrophagocytosis by fluo-
rescence microscopy. Jak2VF erythrocytes showed increased 
uptake by either WT or Jak2VF macrophages (Figure 4B). 
Erythrophagocytosis rather than surface binding of erythro-
cytes by phagocytes was confirmed by reconstructed 3D im-
ages obtained by fluorescence confocal microscopy, as well as 
overlay on bright field images (Online Figure VIA and VIB). 
To assess whether the findings of aberrant erythrophagocy-
tosis with mouse Jak2VF erythrocytes could be recapitulated 
Figure 3. Increased necrotic core in advanced lesions of Jak2VF mice. A, Representative H&E (hematoxylin and eosin)-stained aortic root lesions and 
quantification of total lesion area of female Ldlr−/− recipients after 12 wk of Western diet (WD). Unpaired t test. Scale bar, 500 μm. B, Representative Masson 
trichrome stain images of lesions. Scale bar, 500 μm. C, Quantification of necrotic core area and (D) as a percentage of total lesion area of female Ldlr−/− 
recipients after 12 wk WD. Mann-Whitney U test. E, Quantification of Mac-3+  (CD107b) macrophage in the lesions of female mice WD-fed for 12 wk. Mann-
Whitney U test. *P<0.05. WT indicates wild-type.
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with human erythrocytes, we obtained human blood samples 
from JAK2VF positive MPN patients and matched control hu-
man subjects. These patients were newly identified, nontreat-
ed, or being treated with aspirin or phlebotomy but not with 
hydroxyurea or ruxolitinib. Incubation of human erythrocytes 
with human macrophages derived from peripheral blood mon-
onuclear cells of healthy human subjects also resulted in ro-
bust erythrophagocytosis (Online Figure VIC). Quantification 
of erythrophagocytosis by flow cytometry indicated increased 
erythrophagocytosis of JAK2VF erythrocytes compared with 
control erythrocytes (Figure 4C and 4D).
Decreased CD47, a Don’t-Eat-Me Signal or 
Increased Calreticulin, an Eat Me Signal, in Jak2VF 
Erythrocytes
Accelerated erythrocyte aging has been proposed to explain in-
creased erythrophagocytosis in some erythrocytosis models.18 
Increased erythrocyte band 4.1a/4.1b ratio has been used as a 
marker for erythrocyte senescence.18 Band 4.1a/4.1b ratio in 
Figure 4. Jak2VF mice displayed marked increase in erythrophagocytosis. A, Representative images of iron staining, immunohistochemistry staining of red 
blood cell (RBC) marker Ter119 and macrophage marker Mac-3 (CD107b) in lesions of female Ldlr−/− recipients after 12 wk Western diet. Scale bar, 100 μm. B, 
Bone marrow–derived macrophages (BMDM; 4′,6-diamidino-2-phenylindole [DAPI], blue) were incubated with 2 million PKH26-labeled erythrocytes (red) overnight 
and quantification of relative RBCs fluorescence intensity. Cells from both male and female mice were used for the assays. Pooled data from 5 independent 
experiments were used for analysis. Scale bar, 50 μm. 2-way ANOVA. C, Erythrophagocytosis rate (Mann-Whitney U test) and (D) RBCs MFI (mean fluorescence 
intensity) of human normal control and JAK2VF patients were measured by flow cytometry. Unpaired t test. *P<0.05, **P<0.01,***P<0.001. WT indicates wild-type.
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mouse Jak2VF erythrocytes was not altered relative to the WT 
erythrocytes (Online Figure VID), suggesting no change of e-
rythrocyte senescence. However, we noticed that band 4.2 was 
markedly decreased in Jak2VF erythrocytes (Online Figure VID 
and VIE). Band 4.2 deficiency has been linked to accelerated 
erythrocyte clearance and marked reduction of CD47,19,20 a mol-
ecule protecting erythrocytes from fortuitous phagocytosis by 
macrophages.21 We assessed erythrocyte surface CD47 levels by 
flow cytometry and found a significant reduction in Jak2VF eryth-
rocytes (Figure 5A and 5B). In contrast, human Jak2VF eryth-
rocytes did not show a decrease in surface CD47 (not shown) 
but rather displayed increased surface calreticulin (Figure 5C), 
consistent with a recent report.22 Surface calreticulin counteracts 
CD47 signaling and promotes phagocytosis of erythrocytes.23 
These results suggest distinct mechanisms promoting erythro-
phagocytosis of human versus mouse Jak2VF erythrocytes.
Defective Efferocytosis in Advanced Lesions in 
Jak2VF Mice
A body of work indicates that efficient efferocytosis of ap-
optotic cells by lesional macrophages is a key event limiting 
necrotic core formation in advanced atherosclerosis.24–26 The 
increased necrotic core in advanced lesions of Jak2VF mice led 
us to assess lesional efferocytosis. The ratio of free versus mac-
rophage-associated apoptotic cells was markedly increased in 
advanced lesions of Jak2VF mice (Figure 6A), indicating defec-
tive efferocytosis. Macrophage MerTK (c-Mer tyrosine kinase) 
serves as a cell surface receptor and signaling molecule medi-
ating efferocytosis, and MerTK has a central role in promoting 
efferocytosis and decreasing necrotic core formation in ather-
osclerotic lesions.24,27 We thus assessed surface MerTK levels 
in vivo in splenic macrophages and levels of soluble MerTK, 
the product of surface MerTK cleavage, generated from the 
cultured macrophages of WT and Jak2VF mice. This showed 
increased cleavage (inset, Figure 6B) and markedly decreased 
cell surface MerTK levels (Figure 6B) in Jak2VF compared 
with WT macrophages, whereas plasma soluble MerTK levels 
showed no change (Online Figure VIF). Importantly, MerTK 
levels in lesional macrophages were markedly decreased in ad-
vanced lesions of Jak2VF mice (Figure 6C; Online Figure VIG 
and VIH). Next, we assessed the potential impact of erythro-
phagocytosis on efferocytosis ex vivo. Coincubation of WT or 
Jak2VF macrophages with erythrocytes and apoptotic Jurkat 
cells led to suppression of efferocytosis of Jurkat cells rela-
tive to incubation with Jurkat cells alone (Figure 6D). WT and 
Jak2VF macrophages did not show difference in efferocytosis. 
In contrast, Jak2VF erythrocytes caused a more pronounced 
suppression of efferocytosis in both WT and Jak2VF macro-
phages (Figure 6D), likely reflecting the increased suscepti-
bility of Jak2VF erythrocytes to erythrophagocytosis. Together, 
these findings suggest that increased uptake of erythrocytes in 
combination with decreased uptake of apoptotic cells by le-
sional macrophages contributes to advanced lesion complexity, 
including increased necrotic core formation in Jak2VF mice.
Increased Inflammatory Activation of Jak2VF 
Macrophage
To assess inflammatory responses, we challenged WT or 
Jak2VF macrophages with lipopolysaccharide (LPS), a stim-
ulus relevant to TLR4/MyD88 (toll-like receptor/myeloid 
differentiation primary response 88) and TLR4/TRIF (TLR4/
TIR [Toll/interleukin 1 receptor]-domain-containing adapt-
er-inducing INF [interferon]-β) signaling pathways that are 
known to promote atherogenesis.28,29 Jak2VF macrophages 
showed increased expression of proinflammatory cytokines 
and chemokines, that is, IL (interleukin)-1β, IL-6, iNOS (in-
ducible nitric oxide synthase), Tnf-α (tumor necrosis factor), 
and MCP-1 (monocyte chemoattractant protein 1; Figure 7A; 
Online Figures IX, XB, and XI). Although IL-6 secretion from 
Jak2VF macrophages was markedly increased, the increase in 
IL-1β secretion after 8-hour LPS stimulation was only moder-
ate (Online Figure VIIA and VIIB), and less pronounced than 
the increase in IL-1β mRNA levels (Figure 7A). Prominent 
IL-1β secretion requires inflammasome activation.30 Indeed, 
Figure 5. Jak2VF mice showed reduced 
surface CD47 expression in erythrocytes. 
Erythrocytes were from chow-fed female mice. 
A, Mean fluorescence intensity of anti-CD47 
antibody bound to erythrocytes (Unpaired t test) 
and (B) percentage of CD47hi erythrocytes by 
flow cytometry. Unpaired t test. C, Percentage 
of calreticulin positive erythrocytes in human 
normal controls and JAK2VF patients. Unpaired 
t test.*P<0.05, ***P<0.001. MFI indicates mean 
fluorescence intensity; RBC, red blood cells; 
and WT, wild-type.
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Figure 6. Defective efferocytosis was associated with decreased macrophage surface MerTK (c-Mer tyrosine kinase) in Jak2VF mice. A, 
Representative images of advanced lesions (12 wk Western diet [WD]-fed) in which apoptotic cells were stained by TUNEL (terminal deoxynucleotidyl 
transferase dUTP nick-end labeling; red), macrophages by Mac-3 (CD107b; green) and nuclei by 4′,6-diamidino-2-phenylindole (DAPI; blue). 
Efferocytosis was assessed as the ratio of free to macrophage-associated TUNEL-positive cells. The red arrow depicts free apoptotic cells and the 
white arrow depicts macrophage-associated apoptotic cells. Scale bar, 20 μm. Unpaired t test. B, Percentage of MerTK positive macrophages in 
total spleen cells as determined by flow cytometry and Western blot of soluble MerTK levels in cultured media of splenic macrophages. Unpaired t 
test. C. Representative single (small) or merged fluorescence images (large) of Mac-3 (red), MerTK (green), or DAPI (blue) and quantification of the 
ratio of MerTK/Mac-3 co-positive to Mac-3 positive macrophages. Scale bar, 100 µm. Mann-Whitney U test. D, Bone marrow–derived wild-type (WT) 
or Jak2VF macrophages were treated with or without 5 million WT or Jak2VF erythrocytes in the presence of apoptotic Jurkat cells for 20 h to assess 
efferocytosis by fluorescence microscope. Data were the representative of 5 independent experiments. 2-way ANOVA. *P<0.05, **P<0.01, ***P<0.001. 
BMDM indicates bone marrow–derived macrophages; RBC, red blood cells; and sol-Mer, soluble MerTK.
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ATP-stimulated IL-1β production from Jak2VF macrophages 
was increased more pronouncedly relative to wild-type cells 
(Figure 7B), consistent with inflammasome activation. To e-
valuate the relevance in vivo, we examined inflammasome 
activation by assessing caspase-1 and caspase-11 cleavage in 
splenic CD11b+ or CD11b− cells. This was markedly increased 
in Jak2VF CD11b+ (Figure 7C) but not WT CD11b+ (Figure 7C) 
or Jak2VF or WT CD11b− cells (not shown), suggesting acti-
vation of both NLRP3 (NLR family pyrin domain-containing 
3) and noncanonical, Caspase-11 dependent macrophage 
inflammasomes.31 Markedly increased IL-1β production from 
the freshly isolated splenic Jak2VF CD11b+ cells, particularly 
in response to LPS, was also consistent with inflammasome 
activation in vivo (Figure 7D). Additional evidence showing 
inflammasome activation came from the finding that plasma 
levels of IL-18, which production depends on and is consid-
ered as a marker of inflammasome activation in vivo,32 were 
markedly increased in Jak2VF mice (Figure 7E).
Although increased proinflammatory responses to LPS 
were consistently detected in briefly cultured concanavalin A 
Figure 7. Jak2VF myeloid cells displayed enhance inflammasome activation. A, ConA (Concanavalin A)-induced peritoneal macrophages were 
challenged with or without 10 ng/mL lipopolysaccharide (LPS) for the indicated time and quantitative polymerase chain reaction analysis of mRNA level 
of IL (interleukin)-1β and IL-6. Data were from 5 independent experiments. 1-way ANOVA. B, ELISA of IL-1β in cultured medium of bone marrow—derived 
macrophage challenged with 10 ng/mL LPS for 1 h followed by 1 mM ATP for 3 h. Baseline was LPS (10 ng/mL) only for 4 h. 1-way ANOVA. C, Western 
blot of caspase-1 and caspase-11 cleavage in splenic CD11b+ cells from female recipients Western diet (WD)-fed for 7 wk. (D) ELISA of IL-1β in cultured 
medium of CD11b+ cells from female recipients WD-fed for 7 wk. Cells were treated with or without 1 μg/mL LPS for 8 h. Data were the representative 
from 4 independent experiments. 2-way ANOVA. E, ELISA of plasma IL-18 in female recipients WD-fed for 8 wk. Unpaired t test. *P<0.05, **P<0.01, 
***P<0.001. WT indicates wild-type.
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(ConA)-elicited mouse peritoneal macrophages (Figure 7A; 
Online Figure VIIC), the responses were less prominent in 
BM-derived macrophages cultured for 7 days (Online Figure 
VIID). ConA is known to induce T-cell proliferation and IFNγ 
responses in vivo33 and JAK2 has an essential role in mediat-
ing IFNγ signaling.34 To explore the possibility that macro-
phages were primed for increased signaling in ConA-treated 
Jak2VF mice, we assessed multiple molecules mediating IFNγ 
and JAK2 signaling. Levels of phosphorylated p38, JNK (c-
Jun N-terminal kinase), and AKT in the non-LPS treated basal 
state were significantly increased in ConA-elicited Jak2VF mac-
rophages, after a brief 6-hour culture in vitro (Online Figure 
VIIIA), and this was largely reversed after 48 hours in culture 
(Online Figure VIIIB). Total and phosphorylated STAT1 (signal 
transducer and activator of transcription 1) were markedly de-
creased, a finding consistent with the negative feedback regula-
tion of STAT1 by IFNγ signaling.35 P38 and JNK are critical in 
mediating TLR4 initiated proinflammatory responses in mac-
rophage.36,37 Inhibition of p38, JNK, or combined inhibition of 
p38 and JNK partially or completely reversed the LPS-induced 
proinflammatory responses of ConA-elicited Jak2VF macro-
phages (Online Figure IX), suggesting that increased priming 
had a major role in the enhanced inflammatory response to LPS. 
We also assessed the potential impact of altered endoplasmic 
reticulum stress or autophagy, which are known to regulate pro-
inflammatory activation of macrophages.38,39 CHOP (CCAAT-
enhancer-binding protein homologous protein) expression, a 
marker of endoplasmic reticulum stress, showed no difference 
between WT and Jak2VF macrophages either in the basal or tu-
nicamycin-induced endoplasmic reticulum stress state (Online 
Figure XA). Rapamycin, an inducer of autophagy, decreased 
the expression of some cytokines in response to LPS, but the ef-
fect was proportionate for WT and Jak2VF macrophages (Online 
Figure XB). JAK1/2 inhibitor, such as ruxolitinib, has been 
approved as a treatment for JAK2VF positive MPN patients.40 
Notably, ruxolitinib reversed the increase in proinflammatory 
cytokine and chemokine expression in Jak2VF macrophages, ex-
cept for Tnf-α (Online Figure XI). In contrast, ruxolitinib failed 
to reverse the increased susceptibility of Jak2VF erythrocytes to 
erythrophagocytosis (Online Figure XC).
Discussion
Our study demonstrates that hematopoietic Jak2VF expression 
in hypercholesterolemic mice results in accelerated athero-
sclerosis with features of plaque instability, consistent with 
the increase in atherothrombotic CVD seen in patients with 
JAK2VF-associated MPN or CH.9,10,12,41 Increased neutrophil 
infiltration because of neutrophilia and neutrophil activation 
likely accounts for accelerated early lesion formation. In con-
trast, advanced atherosclerotic lesions displayed increased 
necrotic cores, increased macrophages, iron deposition, and 
evidence of erythrophagocytosis: similar features have been 
associated with atherosclerotic plaque instability in humans.17
On a mechanistic level, Jak2VF macrophages displayed 
increased cleavage and reduced surface levels of MerTK 
in association with defective efferocytosis in advanced le-
sions, likely contributing to increased necrotic core formation 
(Figure 8).42,43 Jak2VF macrophages showed increased inflam-
matory responses, including p38 MAPK (mitogen-activated 
protein kinase) activation likely promoting MerTK cleavage.44 
There was marked inflammasome activation in Jak2VF mac-
rophages leading to increased IL-1β secretion and increased 
IL-18 plasma levels. Increased production of macrophage in-
flammatory cytokines could contribute to increased neutro-
phil production and activation and entry of leukocytes into 
lesions.45,46 Augmented phagocytosis of RBC by macrophages 
likely reflected both increased RBC production, as well as in-
trinsic RBC defects which were seen in both mice and humans. 
Erythrophagocytosis was shown to suppress efferocytosis, sug-
gesting a mechanistic link between these 2 processes. Thus, 
our studies demonstrate that the mechanisms underlying the 
proatherogenic effect of Jak2VF are multifaceted, involving dif-
ferent hematopoietic lineages and their interactions (Figure 8).
Aberrant hematopoiesis and neutrophil infiltration of le-
sions were associated with increased early atherosclerosis in 
Jak2VF mice, as reported in other models of neutrophil over-
production.15 Consistent with a major role of neutrophils, in-
creased rolling and firm adhesion of neutrophils was shown 
by intravital microscopy of carotid arteries in Jak2VF mice. 
Platelet activation, neutrophil activation, platelet/neutrophil 
and platelet/monocyte aggregates which were prominently 
increased in Jak2VF mice are known to promote recruitment 
of inflammatory leukocytes into lesions.47,48 Importantly, sev-
eral of these atherogenic propensities, such as basal platelet 
P-selectin exposure and platelet-monocyte aggregates, were 
augmented by interaction of hypercholesterolemia with the 
Jak2VF mutation. In addition, hypercholesterolemia interacted 
with the Jak2VF to synergistically increase the BM hemato-
poietic stem cell population, possibly reflecting cross-talk 
between JAK2VF signaling with signaling pathways that are 
activated by cholesterol accumulation in hematopoietic stem 
and progenitor cells.49 This raises the possibility that hyper-
cholesterolemia could promote the evolution of CH.
Erythophagocytosis has been described as a prominent fea-
ture in complex human atherosclerotic lesions and proposed to 
promote macrophage foam cell formation and lesional necrotic 
core formation.17 Erythrocyte and macrophage markers colo-
calize in or around lesional necrotic cores in advanced human 
atherosclerotic lesions, suggesting that erythrophagocytosis 
may contribute to plaque instability.17 Increased erythropha-
gocytosis seemed to involve different mechanisms in mouse 
versus human RBCs—with decreased levels of CD47, a don’t-
eat-me signal in mice, and increased levels of calreticulin, a 
prophagocytic signal in human RBCs. The mechanisms re-
sponsible for increased RBC entry into lesions are uncertain 
but could involve the observed increase in formation of RBC-
leukocyte aggregates which could carry RBCs from the arte-
rial lumen into the subendothelial space. One limitation of the 
study is use of female Ldlr−/− mice only as recipients for ath-
erosclerosis studies. Nevertheless, both male and female mice 
were used for in vitro assays of erythrophagocytosis, indicating 
that the altered erythrophagocytosis was not limited to females.
The elevated expression of multiple proinflammatory cy-
tokines and chemokines in Jak2VF macrophage in response 
to LPS stimulation suggests that heightened inflammation 
also contributes to accelerated atherosclerosis in Jak2VF 
mice. Increased lesional inflammation could trigger cleav-
age of cell surface MerTK in macrophages in Jak2VF mice, 
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leading to defective efferocytosis and increased necrotic core 
formation.24 Cleavage of macrophage cell surface MerTK is 
primarily mediated by ADAM17 (ADAM metallopeptidase 
domain 17), and this process can be upregulated by TLR4 and 
p38 MAPK signaling44 which was increased in Jak2VF mac-
rophages. Therefore, proinflammatory macrophage activation 
in Jak2VF mice could exacerbate atherosclerosis by impaired 
efferocytosis via p38 MAPK and by proinflammatory cyto-
kine and chemokine production. As previously reported,31 
there was no detectable inflammasome activation in WD-fed 
Ldlr−/− mice transplanted with wild-type BM. However, there 
was prominent inflammasome activation in splenic CD11b+ 
cells which includes macrophages in Jak2VF mice. The in-
creased production of IL-1β and possibly IL-18 could also 
contribute to neutrophilia and neutrophil infiltration detected 
in Jak2VF mice.45,46,50
Another shortcoming of our study is that it involved pan-
hematopoietic Jak2VF and thus abnormalities in hematopoie-
sis may have contributed more prominently to atherogenesis 
than in a true CH model.10 Although prospectively studied CH 
subjects did not have abnormal blood cell counts at baseline,51 
qualitative changes in blood cell function, as well as develop-
ment of myelo-proliferation in some patients,52 seem likely. In 
humans carrying mutations that cause CH and increased CVD 
risk, the single abnormality in blood cell phenotypes was an 
increase in erythrocyte anisocytosis51 which was also prom-
inent in Jak2VF mice and is a known CVD risk factor in the 
general population.53,54 We speculate that anisocytosis may be 
a marker of aberrant erythrocyte properties, possibly reflect-
ing increased erythrocyte production or interactions between 
inflammatory myeloid cells and erythroblasts in the BM,55 that 
predisposes to atherosclerosis, for example by stimulation of 
erythhrophagocytosis in atherosclerotic lesions.
The recommended treatment for low-risk polycythemia 
vera patients includes phlebotomy and low dose aspirin.56,57 
Current recommendations suggest that the hematocrit should 
be maintained <45%41 because higher hematocrits are associ-
ated with increased cardiovascular death and major thrombo-
sis in polycythemia vera patients.41 Our findings suggest that 
Jak2VF erythrocytes may have a direct role in promoting ad-
vanced atherosclerosis and plaque instability, raising the pos-
sibility that even lower levels of hematocrit may be desirable. 
Finally, our findings highlight the importance of increased my-
elopoiesis, proinflammatory macrophage activation, platelet 
activation, and PLA (platelet/leukocyte aggregate) formation 
in atherogenesis, suggesting the need for effective anti-plate-
let and cytoreductive therapies in MPNs and perhaps in CH. 
Since many of the underlying atherogenic mechanisms were 
aggravated by hypercholesterolemia in Jak2VF mice, control of 
LDL cholesterol via statins and PCSK9 (proprotein convertase 
subtilisin/kexin type 9) mAbs (monoclonal antibodies) may 
be particularly important in patients with JAK2VF-associated 
MPN or CH. Finally, the recent demonstration in the CANTOS 
trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes 
Study) that IL-1β antibodies reduced coronary heart disease 
opens a new vista on anti-inflammatory therapies as a treat-
ment for atherosclerosis,58 and our findings suggest that pa-
tients with CH or MPN may particularly benefit from this or 
other anti-inflammatory therapies.
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